Galena Biopharma has reported a net loss of $6.26m, or $0.09 per share, for the third quarter ended 30 September 2012 compared to a net loss of $5.47m, or $0.09 per share, for the third quarter ended 30 September 2011.
Operating loss for third quarter of 2012 was $5.53m compared to operating loss $3.43m for the third quarter of 2011.
The company reported a net loss of $31.22m, or $0.49 per share, for the nine months ended 30 September 2012 compared to a net loss of $13.07m, or $0.21 per share, for the nine months ended 30 September 2011.
Operating loss of $15.62m was reported for the first nine months of 2012 compared to operating loss of $8.89m for the first nine months of 2011.
Galena president and chief executive officer Mark Ahn said the company progressed in accelerating patient enrollment in the NeuVax Phase 3 PRESENT trial.
"We have strengthened our team and intellectual property, and have opened 40 sites in North America and started opening an additional 40 sites in Western and Eastern Europe, Russia, Ukraine and Israel as planned. 2013 will be a significant year of operational and business development milestones for the company," Ahn added.